SAN DIEGO, July 25, 2019 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, announced today
that the company will release financial results for the second
quarter 2019, after the market close on Thursday, August 1, 2019.
The company will host a conference call to discuss financial
results and general corporate updates beginning at 4:30 p.m. Eastern Time on Thursday, August 1,
2019. To participate on the conference call, please dial
(844) 850-0543 from the U.S. or (412) 317-5199 from outside the
U.S. In addition, following the completion of the call, a telephone
replay will be accessible until August 8,
2019 by dialing (877) 344-7529 from the U.S. or (412)
317-0088 from outside the U.S. and entering conference ID #
10132584. Those interested in listening to the conference
call live via the internet may do so by visiting the Investor
Relations section of Viking's website at
www.vikingtherapeutics.com. An archive of the webcast will be
available for 30 days on the company's website at
www.vikingtherapeutics.com.
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical
company focused on the development of novel, orally available,
first-in-class or best-in-class therapies for the treatment of
metabolic and endocrine disorders. Viking's research and
development activities leverage its expertise in metabolism to
develop innovative therapeutics designed to improve patients'
lives. The company's clinical programs include VK2809, a
novel, orally available, small molecule selective thyroid hormone
receptor beta agonist for the treatment of lipid and metabolic
disorders, including non-alcoholic steatohepatitis (NASH). In
a Phase 2 trial for the treatment of non-alcoholic fatty liver
disease (NAFLD) and elevated LDL-C, patients who received VK2809
demonstrated statistically significant reductions in LDL-C and
liver fat content compared with patients who received
placebo. The company is also developing VK0214, a novel,
orally available, small molecule selective thyroid hormone receptor
beta agonist for the treatment of X-linked adrenoleukodystrophy
(X-ALD).
Viking's other programs include VK5211, an orally available,
non-steroidal selective androgen receptor modulator. In a
Phase 2 trial in patients recovering from hip fracture, patients
who received VK5211 experienced significant improvements in
measures of lean body mass compared with patients who received
placebo. Other programs also include VK0612, a
first-in-class, orally available drug candidate in Phase 2
development for the treatment of type 2 diabetes as well as two
earlier-stage programs targeting metabolic diseases and
anemia. The company holds exclusive worldwide rights to a
portfolio of five therapeutic programs, including those noted
above, which are based on small molecules licensed from Ligand
Pharmaceuticals Incorporated.
Follow Viking on Twitter @Viking_VKTX.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-second-quarter-2019-on-august-1-2019-300890560.html
SOURCE Viking Therapeutics, Inc.